Nature Search

Programmable RNA acetylation with CRISPR–Cas13

Yu et al. developed a programmable RNA acetylation system using dCas13–eNAT10 to specifically install N⁴-acetylcytidine on target RNAs in cells and in vivo, enabling functional studies of RNA acetylation, and revealed the unique role of RNA acetylation in transcript localization.

Jihwan Yu
Juae Jin
Won Do Heo
Research02 Jun 2025
Nature Chemical Biology

P: 1-14
Lineage-specific pathogenicity, immune evasion, and virological features of SARS-CoV-2 BA.2.86/JN.1 and EG.5.1/HK.3

Here, the authors show that a single mutation in JN.1 spike, L455S, confers better spike cleavage and enhances virus infectivity in differentiated primary human nasal epithelial cells while increasing immune evasiveness, contributing to the efficient spread of JN.1.

Yuanchen Liu
Xiaoyu Zhao
Hin Chu
ResearchOpen Access09 Oct 2024
Nature Communications

Volume: 15, P: 1-17
Vaccine-induced protection against SARS-CoV-2 requires IFN-γ-driven cellular immune response

Protective immunity against SARS-CoV-2 relies on both antibodies and a T cell dependent response, however, direct experimental evidence for the contribution of cellular immunity is limited. Here authors present a mouse model that is susceptible to SARS-CoV-2 and lacks B cells to demonstrate the emergence of efficient cellular immune response against SARS-CoV-2 upon vaccination or viral challenge.

Xiaolei Wang
Terrence Tsz-Tai Yuen
Jian-Dong Huang
ResearchOpen Access10 Jun 2023
Nature Communications

Volume: 14, P: 1-15
Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2

The B.1.1.529/Omicron variant of SARS-CoV-2 is resistant to neutralization by serum not only from patients who recovered from COVID-19, but also from individuals vaccinated with one of the four widely used COVID-19 vaccines.

Lihong Liu
Sho Iketani
David D. Ho
Research23 Dec 2021
Nature

Volume: 602, P: 676-681
An orally available M^pro inhibitor is effective against wild-type SARS-CoV-2 and variants including Omicron

An inhibitor of the SARS-CoV-2 main protease (Mpro), Y180, showed therapeutic efficacy against wild-type SARS-CoV-2 and its variants including Omicron after oral administration and improved survival in a humanized mouse model.

Bao-Xue Quan
Huiping Shuai
Shengyong Yang
Research27 Apr 2022
Nature Microbiology

Volume: 7, P: 716-725
Enhanced replication of SARS-CoV-2 Omicron BA.2 in human forebrain and midbrain organoids

Yuxin Hou
Chang Li
Hin Chu
ResearchOpen Access20 Nov 2022
Signal Transduction and Targeted Therapy

Volume: 7, P: 1-4
Coronaviruses exploit a host cysteine-aspartic protease for replication

Coronaviruses exploit the host caspase-6 to cleave coronavirus nucleocapsid protein into fragments with interferon-antagonizing activity to facilitate virus replication.

Hin Chu
Yuxin Hou
Kwok-Yung Yuen
Research03 Aug 2022
Nature

Volume: 609, P: 785-792
Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron

The replication and pathogenicity of the Omicron variant of SARS-CoV-2 is attenuated compared with the original strain and other variants.

Huiping Shuai
Jasper Fuk-Woo Chan
Hin Chu
Research21 Jan 2022
Nature

Volume: 603, P: 693-699
Potent and broadly neutralizing antibodies against sarbecoviruses induced by sequential COVID-19 vaccination

Xiaoyu Zhao
Tianyi Qiu
Pengfei Wang
ResearchOpen Access06 Feb 2024
Cell Discovery

Volume: 10, P: 1-21
A new generation M^pro inhibitor with potent activity against SARS-CoV-2 Omicron variants

Chong Huang
Huiping Shuai
Shengyong Yang
ResearchOpen Access16 Mar 2023
Signal Transduction and Targeted Therapy

Volume: 8, P: 1-13

Search

Filter By:

Search

Quick links